Michelle Berrey, CEO of Durham-based drug developer Chimerix (Nasdaq: CMRX), might be down, but she isn’t out.
On Monday, the biotechnology company reported a failed trial. Berrey hoped that the clinical trial would show that Chimerix’s experimental drug brincidofovir could prevent a virus common in some transplant patients.
